Elusys Therapeutics

Elusys Therapeutics was a United States biopharmaceutical company established in 1998 in Pine Brook, New Jersey, and later associated with Morristown, New Jersey. The company was created around a biological technology developed by Ronald P. Taylor, a professor of biochemistry and molecular genetics at the University of Virginia. Taylor's work concerned heteropolymers: engineered protein complexes designed to bind a disease-causing pathogen on one side and a red blood cell on the other. The resulting complex could cause circulating pathogens to be carried to the liver, where they could be removed from the bloodstream. In preclinical animal work described in the company's history, the approach was able to clear targeted pathogens within approximately two hours. The technology attracted partial support from the United States National Institutes of Health and the Defense Advanced Research Projects Agency. Seed-One Ventures helped arrange additional financing and established Elusys as a vehicle for developing the research commercially. Jeff Wolf, Seed-One's managing partner, served as Elusys's founding chief executive and recruited Stephen Sudovar, a former president of Roche Laboratories, to lead the company. Wolf also assembled a board with experience in large pharmaceutical companies and the United States Food and Drug Administration. Elusys initially tested its heteropolymer platform using two chemically linked monoclonal antibodies in a lupus-related application before concentrating on infectious-disease indications. The company's principal program became Anthim, also known as obiltoxaximab. Anthim is a monoclonal antibody intended to neutralize the protective antigen associated with Bacillus anthracis, the bacterium that causes anthrax. Elusys developed the program with the University of Texas at Austin and the United States Army Medical Research Institute of Infectious Diseases. Because inhalational anthrax was regarded as a potential bioterrorism and biodefense threat, the program received substantial United States government support. The Department of Health and Human Services awarded Elusys a five-year contract in 2010 for development of an intravenous formulation, followed by a 2011 contract supporting an intramuscular formulation and a 2012 award for additional efficacy testing. The Food and Drug Administration accepted biologics license applications covering both intravenous and intramuscular administration in June 2015. The application relied on efficacy findings from animal models together with safety information from human volunteers, a regulatory pathway used for certain biodefense products where conventional human efficacy trials are not feasible. In March 2016, the FDA approved Anthim for treatment of inhalational anthrax in combination with appropriate antibacterial drugs. The approval also covered prevention of inhalational anthrax when alternative therapies were unavailable or inappropriate. In November 2015, before the approval, the company received a further five-year federal contract supporting production and prospective delivery of Anthim to the Strategic National Stockpile. Beyond its lead product, Elusys positioned its heteropolymer and antibody capabilities as potentially applicable to a wider range of blood-borne infections. The company was also a member of the Alliance for Biosecurity, a coalition involving companies and scholars focused on vaccines, therapeutics, and other countermeasures for pandemics and biological attacks. Public reference material describes the company primarily through its Anthim development program and does not establish a current operating status, a later parent company, or a broader commercial product portfolio.

Elusys Therapeutics grew out of research by Ronald P. Taylor at the University of Virginia into engineered heteropolymers. These complexes were designed to connect a specific pathogen with red blood cells, using the body's natural blood-clearing processes to direct the tagged pathogen to the liver for destruction. The concept was supported in part by the National Institutes of Health and the Defense Advanced Research Projects Agency. Animal studies cited in the company's account indicated that the method could remove targeted pathogens from circulation rapidly. Seed-One Ventures arranged additional funding and formed Elusys Therapeutics in 1998 in Pine Brook, New Jersey, to commercialize the technology. Jeff Wolf, Seed-One's managing partner, became the founding chief executive. He recruited Stephen Sudovar, previously president of Roche Laboratories, as chief executive and helped populate the board with pharmaceutical and FDA experience. The company initially explored a lupus application using chemically linked monoclonal antibodies, but its development strategy later shifted toward infectious disease and biodefense. Elusys's central program was Anthim, the brand name for obiltoxaximab, a monoclonal antibody directed at the protective antigen of Bacillus anthracis. The program was developed with the University of Texas at Austin and the United States Army Medical Research Institute of Infectious Diseases. Federal biodefense funding became central to the program: a 2010 Department of Health and Human Services contract supported an intravenous formulation, a 2011 contract supported an intramuscular formulation, and a 2012 award funded further efficacy work. In 2015, the FDA accepted biologics license applications for both administration routes. The applications used animal efficacy studies and human safety data, reflecting the difficulty of conducting conventional efficacy trials for inhalational anthrax. In November 2015, Elusys received a further federal contract for Anthim production and future delivery to the Strategic National Stockpile. In March 2016, the FDA approved Anthim for treatment of inhalational anthrax in combination with suitable antibacterial drugs. The approval also included prevention when other therapies were unavailable or inappropriate. The company participated in the Alliance for Biosecurity, linking it to broader efforts to develop countermeasures for pandemics and biological attacks. Available reference material does not document a complete later corporate history, subsequent ownership, a current executive team, or the commercial status of the company and its website. Accordingly, those fields remain unconfirmed.

• 2016

  Anthim receives FDA approval

  [1]Elusys Therapeuticsen.wikipedia.org

  Obiltoxaximab was approved for treatment and certain preventive uses involving inhalational anthrax.

• 2015

  FDA accepts Anthim applications

  [1]Elusys Therapeuticsen.wikipedia.org

  The FDA accepted biologics license applications for intravenous and intramuscular Anthim.

• 2012

  Anthim efficacy testing receives additional funding

  [1]Elusys Therapeuticsen.wikipedia.org

  Elusys obtained additional government funding for efficacy testing of its anthrax antibody.

• 2011

  Intramuscular formulation program receives federal support

  [1]Elusys Therapeuticsen.wikipedia.org

  A second five-year award supported development of an intramuscular Anthim formulation for prevention-related use.

• 2010

  Federal contract supports intravenous Anthim development

  [1]Elusys Therapeuticsen.wikipedia.org

  The Department of Health and Human Services awarded a five-year contract for development of an intravenous anthrax treatment.

• 1998

  Elusys Therapeutics is established

  [1]Elusys Therapeuticsen.wikipedia.org

  Seed-One Ventures helped establish Elusys in New Jersey to commercialize Ronald P. Taylor's heteropolymer research.

A biotechnology developer focused on antibody-based therapies and biodefense products for serious infectious diseases, especially inhalational anthrax.

• Monoclonal antibody / biodefense therapeutic · 2016

  Anthim

  Anthim is the brand name for obiltoxaximab, a monoclonal antibody targeting the protective antigen of Bacillus anthracis. It was developed for inhalational anthrax, with treatment use alongside appropriate antibacterial drugs and preventive use when alternative therapies were unavailable or unsuitable. The development program included intravenous and intramuscular administration routes and relied on animal efficacy studies together with human safety data.

• Biotechnology platform

  Heteropolymer antibody platform

  Elusys's platform used engineered protein complexes capable of binding a selected pathogen and a red blood cell at the same time. The intended mechanism was to redirect pathogen-bearing red blood cells to the liver for clearance. The company investigated the approach in early work involving chemically linked monoclonal antibodies and described it as potentially applicable to multiple blood-borne diseases.

• 2015

  Advance Anthim toward regulatory approval and stockpilingProduct launch

  Background

  After FDA acceptance of applications for two administration routes, the company also secured government support for production and future delivery.

  Action taken

  Elusys pursued approval and entered a five-year production and delivery arrangement for the Strategic National Stockpile.

  Aftermath

  Anthim was approved by the FDA in March 2016 for specified treatment and prevention uses involving inhalational anthrax.

  Five-year production and delivery contract. $44.9 million (November 2015)

  Source

• 2010

  Prioritize government-supported anthrax biodefense developmentStrategy

  Background

  Elusys concentrated its development resources on Anthim as concern over anthrax exposure and bioterrorism created demand for medical countermeasures.

  Action taken

  The company pursued federal support for intravenous and later intramuscular formulations of obiltoxaximab.

  Aftermath

  The program progressed through additional efficacy testing, FDA review, approval, and a Strategic National Stockpile supply contract.

  Five-year development contract. $143 million (2010)

  Source

1. 1Elusys Therapeuticsen.wikipedia.org
2. 2Elusys Therapeutics official websiteelusys.com